Paper Review Records
All Paper Review Records
13 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
111
days
Peripheral cannabinoid-1 receptor antagonists in clinical development: therapeutic potential for the management of obesity and related metabolic disorders
AuthorsJonanne Talebloo; Esha Chawla; Donya Shahamati; Swas Shiv; Kishore M. Gadde
Affiliations1. University of California Irvine School of Medicine; 2. Vanderbilt University School of Medicine; 3. University of California Irvine; 4. Boston University
131
days
Taxane therapy in mCRPC: current positioning and emerging strategies to overcome resistance
AuthorsLing Wang; Yanfeng Tang; Mingsheng Liu; Hongqing Zhou; Hao Zeng; Bo Tang
Affiliations1. Institute of Urology, Sichuan Clinical Research Center for Kidney and Urologic Diseases, West China Hospital, Sichuan University; 2. Qujing Affiliated Hospital of Kunming Medical University
45
days
Cognitive-enhancing drugs in Phase II clinical trials for Alzheimer’s disease: emerging therapeutic candidates
AuthorsPatricia Regina Manzine; Marina Carrasco; Thaís Antonia Alves Fernandes; Suelen Santos Alves; Laura Guzman; Leila Driouech; Mireia Millet-Sigalat; Norberto Garcia Cairasco; Jordi Olloquequi; M. Emilia Juan; Miren Ettcheto; Marcia Regina Cominetti; Antoni Camins
Affiliations1. University of Barcelona; 2. Instituto de Salud Carlos III; 3. Institut d’Investigació Sanitària Pere Virgili (IISPV); 4. Federal University of São Carlos; 5. University of São Paulo; 6. Universidad Autónoma de Chile; 7. Trinity College Dublin
153
days
Budigalimab: a viable option for patients with advanced solid tumors
AuthorsAlice Mogenet; Laurent Greillier
Affiliations1. Aix Marseille University, APHM, INSERM, CNRS, CRCM
47
days
Lonvoguran ziclumeran: a CRISPR-CAS9-based gene therapy for the treatment of hereditary angioedema
AuthorsLong Hoang Luong; Shane Stone; Van Bui; Bharosha Bhattarai; Mai Thi Vu; E. Pelinsu Aydin; Timothy Craig
Affiliations1. Kansai Medical University; 2. Hanoi Medical University; 3. Penn State Health; 4. Vinmec Times City International Hospital and Vinmec-VinUni Institute of Immunology, VinUniversity; 5. University of Health Sciences İzmir
219
days
Investigational IL-17A antagonist in the treatment of psoriatic arthritis - a review
AuthorsOsariemen Osunbor; Jan René Nkeck; Adewale O. Adebajo
Affiliations1. Barnsley Hospital NHS Foundation Trust; 2. University of Yaoundé I; 3. University of Sheffield
159
days
Vidofludimus calcium for the treatment of multiple sclerosis: development rationale, mechanism of action, and early trial data
AuthorsMatej Ondrus; Robert J. Fox; Evelyn Peelen; Juliano Fonseca; Valentina Sciacca; Ines Sanchez-Gomez; Jacques Arend; Alexandra Herrmann; Maria Samcova; Christian Gege; Lesia Havrylova; Hella Kohlhof; Jason Tardio; Daniel Vitt; Andreas Muehler
Affiliations1. Immunic AG; 2. Cleveland Clinic
161
days
Advancements in longevity pharmacology research – are we finally seeing clinical progression?
AuthorsMadia Lozupone
Affiliations1. University of Bari Aldo Moro; 2. Azienda Sanitaria Locale (ASL) Bari
131
days
Targeting fatty acid synthase inhibitors for the treatment of acne vulgaris: what can we learn from early phase investigations
AuthorsDániel Törőcsik; Dóra Tiszai; Christos C. Zouboulis
Affiliations1. University of Debrecen; 2. HUN-REN-UD Allergology Research Group; 3. University Pharmacy, Clinical Centre, University of Debrecen; 4. Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg
69
days
Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date
AuthorsAndrea J. Mothe; Philippe P. Monnier; Charles H. Tator; Michael G. Fehlings
Affiliations1. Krembil Brain Institute & University Health Network; 2. University of Toronto
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days